Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields
F P Costa, A C de Oliveira, R Meirelles, M C C Machado, T Zanesco, R Surjan, M C Chammas, M de Souza Rocha, D Morgan, A Cantor, J Zimmerman, I Brezovich, N Kuster, A Barbault, B Pasche, F P Costa, A C de Oliveira, R Meirelles, M C C Machado, T Zanesco, R Surjan, M C Chammas, M de Souza Rocha, D Morgan, A Cantor, J Zimmerman, I Brezovich, N Kuster, A Barbault, B Pasche
Abstract
Background: Therapeutic options for patients with advanced hepatocellular carcinoma (HCC) are limited. There is emerging evidence that the growth of cancer cells may be altered by very low levels of electromagnetic fields modulated at specific frequencies.
Methods: A single-group, open-label, phase I/II study was performed to assess the safety and effectiveness of the intrabuccal administration of very low levels of electromagnetic fields amplitude modulated at HCC-specific frequencies in 41 patients with advanced HCC and limited therapeutic options. Three-daily 60-min outpatient treatments were administered until disease progression or death. Imaging studies were performed every 8 weeks. The primary efficacy end point was progression-free survival 6 months. Secondary efficacy end points were progression-free survival and overall survival.
Results: Treatment was well tolerated and there were no NCI grade 2, 3 or 4 toxicities. In all, 14 patients (34.1%) had stable disease for more than 6 months. Median progression-free survival was 4.4 months (95% CI 2.1-5.3) and median overall survival was 6.7 months (95% CI 3.0-10.2). There were three partial and one near complete responses.
Conclusion: Treatment with intrabuccally administered amplitude-modulated electromagnetic fields is safe, well tolerated, and shows evidence of antitumour effects in patients with advanced HCC.
Conflict of interest statement
AB and BP have filed a patent related to the use of electromagnetic fields for the diagnosis and treatment of cancer. AB and BP are founding members of TheraBionic LLC.
Figures
References
- Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De GJ, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24(26): 4293–4300
- Amato D, Pasche B (1993) An evaluation of the safety of low energy emission therapy (published erratum appears in Compr Ther 1994;20(12):681. Compr Ther 19: 242–247
- Barbault A, Costa F, Bottger B, Munden R, Bomholt F, Kuster N, Pasche B (2009) Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. J Exp Clin Cancer Res 28(1): 51.
- Boige V, Raoul JL, Pignon JP, Bouche O, Blanc JF, Dahan L, Jouve JL, Dupouy N, Ducreux M (2007) Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer 97(7): 862–867
- Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5): 1208–1236
- Cance WG, Stewart AK, Menck HR (2000) The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985–1996. Cancer 88(4): 912–920
- Chan SL, Mo FK, Johnson PJ, Hui EP, Ma BB, Ho WM, Lam KC, Chan AT, Mok TS, Yeo W (2009) New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 27(3): 446–452
- Chang I (2003) Finite element analysis of hepatic radiofrequency ablation probes using temperature-dependent electrical conductivity. Biomed Eng Online 2: 12.
- Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1): 25–34
- Choi BI (2007) Doppler and harmonic ultrasound for hepatocellular carcinoma. Hepatol Res 37(Suppl 2): S172–S177
- Chuah B, Lim R, Boyer M, Ong AB, Wong SW, Kong HL, Millward M, Clarke S, Goh BC (2007) Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncol 46(2): 234–238
- Cohn AL, Myers JW, Mamus S, Deur C, Nicol S, Hood K, Khan MM, Ilegbodu D, Asmar L (2008) A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma. Invest New Drugs 26(4): 381–386
- Dollinger MM, Behrens CM, Lesske J, Behl S, Behrmann C, Fleig WE (2008) Thymostimulin in advanced hepatocellular carcinoma: a phase II trial. BMC Cancer 8: 72.
- ICNIRP (1998) Guidelines for limiting exposure to time-varying electric, magnetic and electromagnetic fields (up to 300 GHz). Health Phys 74: 494–522
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. Cancer J Clin 61(2): 69–90
- Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. Cancer J Clin 60(5): 277–300
- Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ (2004) Cancer statistics, 2004. Cancer J Clin 54(1): 8–29
- Kassianides C, Kew MC (1987) The clinical manifestations and natural history of hepatocellular carcinoma. Gastroenterol Clin North Am 16(4): 553–562
- Kelly TL, Kripke DF, Hayduk R, Ryman D, Pasche B, Barbault A (1997) Bright light and LEET effects on circadian rhythms, sleep and cognitive performance. Stress Med 13: 251–258
- Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362(9399): 1907–1917
- Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ, for the Panel of Experts in HCC-Design Clinical Trials (2008a) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100(10): 698–711
- Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319): 1734–1739
- Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, the SHARP Investigators Study Group (2008b) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4): 378–390
- Maruyama H, Yoshikawa M, Yokosuka O (2008) Current role of ultrasound for the management of hepatocellular carcinoma. World J Gastroenterol 14(11): 1710–1719
- Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334(11): 693–700
- Pasche B, Erman M, Hayduk R, Mitler M, Reite M, Higgs L, Dafni U, Amato D, Rossel C, Kuster N, Barbault A, Lebet JP (1996) Effects of low energy emission therapy in chronic psychophysiological insomnia. Sleep 19: 327–336
- Pasche B, Erman M, Mitler M (1990) Diagnosis and management of insomnia. N Engl J Med 323: 486–487
- Pasche B, Barbault A (2003) Low-energy emission therapy: current status and future directions. In Bioelectromagnetic Medicine, Rosch PJ, Markov MS (eds) pp 321–327. Marcel Dekker Inc.: New York, NY
- Reite M, Higgs L, Lebet JP, Barbault A, Rossel C, Kuster N, Dafni U, Amato D, Pasche B (1994) Sleep inducing effect of low energy emission therapy. Bioelectromagnetics 15: 67–75
- Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, Ibrahim SM, Sato KT, Baker T, Miller FH, Newman S, Omary R, Abecassis M, Benson III AB, Salem R (2009) Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 27(34): 5734–5742
- Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RSJ, Rafii S, Schwartz JD (2008) Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26(18): 2992–2998
- Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1): 1–10
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3): 205–216
- Thomas MB, Zhu AX (2005) Hepatocellular carcinoma: the need for progress. J Clin Oncol 23(13): 2892–2899
Source: PubMed